Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSC-ILD)

NCT05878717 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT05878717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05878717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSC-ILD)
Lead sponsor
GlaxoSmithKline
Phase
Phase 2/3
Overall status
Recruiting
Start date
September 13, 2023
Completion date
October 25, 2029
Enrollment
300 (estimated)
Sites
134

Conditions

As the registry lists them; a condition with its own page is linked.

scleroderma, systemic, systemic sclerosis associated interstitial lung disease